NervGen Pharma

Inactive

NGEN.V (VAN)

NervGen Pharma Corp. is a biotechnology company developing treatments to promote nervous system repair after neurotrauma and in neurological diseases. Its lead candidate, NVG-291, is in a Phase 1b/2a trial for spinal cord injury, stroke, multiple sclerosis, and Alzheimer's disease. NVG-300 is in preclinical testing for ischemic stroke and SCI. The company licenses technology from Case Western Reserve University and was founded in 2017 in Vancouver, Canada.